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OBJECTIVES: The aim of this study is to evaluate the access of patients with lung cancer in a densely populated
area of Sa˜o Paulo to the Brazilian Public Health System, focusing on the time spent from symptom onset or
initial diagnosis until the beginning of treatment.
METHODS: We retrospectively reviewed 509 patients with malignant lung neoplasms who were admitted to a
single reference oncology center of the public health system between July 2008 and December 2014. Patients
were considered eligible for this study if they were older than 18 years and had not undergone any previous
oncology treatment when they were admitted to the institution. The following data were collected from all
patients: age, gender, smoking status, tumor staging, time from the when the first symptoms were experienced
by the patient to when the patient was diagnosed with cancer, time from the first appointment to cancer
diagnosis, and time from when the patient was diagnosed with cancer to the initiation of treatment.
RESULTS: The median time from symptom onset to diagnosis was three months. From the first appointment to
diagnosis, the median time interval was one month; however, 79% of patients were diagnosed in up to two
months. The median time from diagnosis to the start of treatment was one month, but most patients (82.5%)
started treatment in up to two months.
CONCLUSION: In our highly populated region with preferential access to the public health system, patients are
required to wait a relatively long time to effectively begin treatment for lung cancer. This type of study is
important to alert medical societies and government health agencies.
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’ INTRODUCTION
Lung cancer is the malignant neoplasm with the highest
incidence worldwide (1,2). In developed countries, the incidence
has decreased in men and remained stable among women,
reflecting a reduction in the rate of smoking in males (3).
Lung cancer is also the leading cause of cancer-related deaths
worldwide, with an estimated 1.1 million deaths in men and
427,400 in women in 2012 (4). These numbers are greater than
the sum of deaths due to breast, prostate and colon cancers and
account for approximately 18% of deaths from all cancers (1).
In 2016 in Brazil, 17,490 new cases of lung cancer were esti-
mated in men and 10,540 in women. These values correspond
to an estimated risk of 16.79 new cases per 100,000 men and
10.75 per 100,000 women. Excluding non-melanoma skin tumors,
lung cancer in men is the second most common malignancy
in the southern (35.17 / 100,000) and midwestern (14.53 /
100,000) regions of Brazil. In the southeastern (19.02 / 100,000),
northeastern (9.75 / 100,000) and northern (8.07 / 100,000)
regions of Brazil, lung cancer is the third most common
cancer among men. For women, lung cancer is the third most
common malignancy in the southern (20.61 / 100,000) and
southeastern (10.56 / 100,000) regions. In the midwestern
(9.37 / 100,000) and northeastern (7.24 / 100,000) regions of
Brazil, lung cancer is the fourth most common malignancy in
women. In the northern region (5.07 / 100,000), lung cancer
is the fifth most common among women (5). Unlike the data
from developed countries, the lung cancer incidence and
mortality in Brazil follow an upward curve, with progres-
sively higher diagnostic and mortality rates. (6). In 1992,
Pereira et al. described the profile and access of lung cancer
patients in the Brazilian Public Health System (SUS). The
author showed data related to the initial staging and warned
about the delay in the diagnostic process (7). However, thisDOI: 10.6061/clinics/2017(11)05
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study did not assess the necessary time to start treatment.
After this study, the literature over the past few decades did
not include another study that assessed the evolution of
health care access of lung cancer patients in the SUS.
The aim of this study is to evaluate the recent access (in the
last six years) of lung cancer patients to the SUS, including
the time required to start treatment.
’ METHODS
This study is part of a research project approved by the
Ethics Review Committee at our institution, registered under
protocol 49258615.4. We retrospectively reviewed 509 patients
with malignant lung neoplasms who were admitted to a single
reference oncology center of the public health system between
July 2008 and December 2014, which were our inclusion criteria.
The median follow-up time was seven months (range 1 –
77 months). Our institution is one of the reference oncology
centers in the state of São Paulo, which is the most densely
populated area of Brazil. Our center is recognized by the
executive board of the public health system as an institution
able to treat any type of cancer, including pediatric cancer.
Patients diagnosed with lung cancer during the study
period were identified by the Cancer Registry database of
our institution. Additional clinical information on individual
patients was collected retrospectively from medical records
kept at our institution. All patients admitted were originally
from public health care units (general practitioners or pulmono-
logists) and required a recommendation to the oncology
center from the executive board of the public health system.
The board of the public health system refers these patients to
one of the reference oncology centers. Patients were con-
sidered eligible for this study if they were older than 18 years
and had not undergone any previous oncology treatment
when they were admitted. All 509 patients were eligible for
this study. We did not find any patients who had undergone
previous oncology treatment or patients younger than 18 years
old. Histopathological exams were registered to confirm lung
cancer diagnoses. All patients admitted to our institution
without histopathological exams were submitted to tumor
biopsy guided by computed tomography (CT), ultrasound or
bronchoscopy. Patients with suspected stage I lung cancer
were subjected to a CT scan that included the thorax, abdo-
men and pelvis. Patients with suspected stage II or more
advanced disease were subjected to positron emission tomo-
graphy (PET) and brain nuclear magnetic resonance imaging.
Patients who were candidates for surgical treatment were
subjected to a frozen biopsy of the lung tumor and the medi-
astinal lymph nodes in the operating room. The following
data were collected from all patients: age range, gender,
smoking status and tumor staging according the American
Joint Committee on Cancer and the International Union
for Cancer Control update of the tumor-node-metastasis
(TNM) cancer staging system (8,9). In this study, we also
evaluated the influence of time until diagnosis and time to
initiate the treatment on the survival of patients with lung
cancer. The data were collected and arranged in the fol-
lowing time intervals:
a) Time (months) from the date when the first symptoms
were experienced by the patient (patient history, PH) to
the date when the patient was diagnosed with cancer (DX);
we excluded 37 patients who were asymptomatic when we
conducted this specific analysis.
b) Time (months) from the date of the first appointment (first
app) with a specialist (oncologist or thoracic surgeon) to
the date when the patient was diagnosed with cancer
(DX); we excluded seven patients from whom we did not
recover this information when we conducted this specific
analysis.
c) Time (months) from the DX date to the starting date of
treatment (TTO).
Statistical Analyses
Descriptive analysis of the data (i.e., distribution and the
presence of outliers) was carried out using measures of
central tendency (median and interquartile range), measures
of dependence (correlation and covariance) and measures of
dispersion (amplitude and/or standard deviation) for con-
tinuous variables and frequency for categorical variables.
Categorical and continuous variables were compared by
Fisher’s exact test or by chi-squared and Mann-Whitney
U tests, respectively. In addition, measures of skewness and a
coefficient of kurtosis were evaluated.
Death related to lung cancer was the principal outcome
evaluated in this study. Kaplan-Meier survival estimates
were used to determine the five-year lung cancer-specific
survival for all patients, and the log-rank (Mantel-Cox
method) and Breslow (generalized Wilcoxon) analyses were
used to compare the differences between factors. The cutoff
values were chosen based on medical literature regarding
delayed treatment in lung cancer (10-12). Survival was cal-
culated from the date of patient admission to our institution
to the date of the last follow-up or until death from any cause.
The data are presented as the medians and 95% confidence
intervals (CIs; lower – upper bounds).
Univariate and multivariate Cox proportional hazard
analyses were performed to investigate the prognostic signi-
ficance of the demographic and predictive risk factors on the
survival outcome of patients with lung cancer. Statistical
analyses were performed using SPSS version 17.0 for
Windows. A two-tailed value of p o 0.05 indicated statis-
tical significance.
’ RESULTS
The demographic characteristics of the 509 lung cancer
patients are summarized in Table 1. The mean age of these
patients was 62.5 years (standard deviation: 11.2 years), and
there was a slight predominance of male (57.8%) over female
(42.2%) patients. More than 75% of these patients were
smokers. Lung adenocarcinomas (37.3%) and squamous cell
carcinoma (28.7%) were the most common types of tumors
observed in the patients, and carcinoid tumors (2.1%) were
the least frequent type. Regarding clinical stages, most
patients (68.3%) came to our hospital when the disease was
already at an advanced stage (stages III and IV). Most of
these patients began receiving treatment at up to 1.5 months
after DX (Table 2). Approximately one-fifth of the patients
were eligible for surgery (20.2%), and lobectomy (67.0%) was
the most frequently performed surgical procedure. For all
patients, including those who received no cancer-specific
treatment, the median overall survival was seven months
(95% CI: 5.7 to 8.2 months), with 34.5% of these patients
surviving for one year and 8.1% surviving for five years.
Patients spent a relevant amount of time waiting during
each interval period. For instance, the median time from PH
to DX was 3 months. From the first app to DX, the median
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time interval was 1 month; however, 79% of patients were
diagnosed in up to 2 months. Finally, the median time from
DX to TTO was 1 month (range: 0 – 17 months), but most
patients (82.5%) started treatment in up to 2 months.
The effects of the time intervals from the development
of the first symptoms to TTO on lung cancer-associated
mortality are shown in the set of Kaplan-Meier survival curves
using the log-rank and/or Breslow statistical tests. A Kaplan-
Meier curve demonstrated a significant negative impact on the
cumulative five-year survival curve for patients who started
treatment up to 1.5 months after DX. The time from PH to DX
and the time from the first app with the general practitioner
to DX were not statistically significant (Figures 1, 2 and 3).
These results were confirmed in the multivariate analysis
(Table 3).
’ DISCUSSION
In Brazil, to the best of our knowledge, one study has
assessed the time from diagnosis to treatment of lung cancer
(7). In 1992, Pereira et al. studied patients at all stages and
not only patients who were candidates for surgical resection
(7). Our study data, obtained 23 years later, suggest that the
time required for lung cancer diagnosis has decreased. The
data also suggest that diagnosis is faster when the patient
can make an appointment with a specialist (i.e., a pulmonol-
ogist, thoracic surgeon or oncologist). Additionally, as far as
we know, this is the first study that evaluated the time to
begin cancer treatment or palliative care across all cancer
stages in the public health system. Other positive results on
the survival from this study are the cancer stage, histological
type of lung cancer and surgical treatment. However, these
results are well stablished in the medical literature.
Pereira et al. reported that only 44.3% of patients were
diagnosed with lung cancer within 90 days. On the other
hand, 45.5% of patients were diagnosed after 120 days.
However, the same study showed that access to the public
health system was fast, with 88% of patients arriving at
the first consultation within 30 days after symptom onset,
but only 10% were initially seen by a specialist in the onco-
pulmonology area.
Our study showed that the median time from PH to DX
was 90 days, and 79% of cases had a lung cancer diagnosis
confirmed within 60 days. Another important finding is that
after the first consultation with a specialist, the median time
to diagnosis was 30 days. These data suggest that in the last
23 years, there was a decrease in the time to diagnosis of lung
cancer and that medical specialists, not generalists, played an
important role in accelerating the time to diagnosis. In the
United States, Nadpara et al. reported a median time between
first symptomatic presentation and diagnosis of approximately
180 days (13). A median diagnostic interval of 113 days (with
an upper quartile value of 249 days) was reported in a recent
English primary care records study of lung cancer patients
diagnosed between 2007 and 2010 (14).
However, regarding the time required to start treatment
after diagnosis, 50% of patients required up to 30 days, 32.5%
required between 30 and 60 days, and 17.5% required more
Table 1 - Demographic characteristics of the 509 lung cancer
patients.
Parameters Total Number %
Patient age (mean±SD), years (62.5±11.2)
Number of patients 509 100%
Gender
Male 294 57.8%
Female 215 42.2%
Histology type of primary tumor
Adenocarcinoma 187 37.3%
11 2.1%
Large cell carcinoma 24 4.7%
Small cell lung cancer 74 14.5%
Squamous cell carcinoma 146 28.7%
Undefined 67 13.2%
Stages of cancer
Ia/Ib 37 7.3%
IIa/IIb 28 5.5%
IIIa/IIIb 74 14.5%
IV 274 53.8%
Extensive a 58 11.4%
Limited b 15 2.9%
Undefined 23 4.5%
Surgical procedure
Yes 103 20.2%
No 406 79.8%
Surgical procedure type
Bi-lobectomy 1 1.0%
Lobectomy 69 67.0%
Pneumectomy 15 14.5%
Segmentectomy 9 8.7%
Thoracotomy 9 8.7%
Disease recurrence
Yes 127 24.9%
No 382 75.1%
Smoker
Yes 400 78.6%
No 109 21.4%
Cigarette packs per year
(mean ± SD) (50.5±32.9)
a Extensive disease: Beyond the ipsilateral hemithorax, which may include
malignant pleural or pericardial effusion or hematogenous metastases
(TNM: T any, N any, M Ia/b; T3-T4 due to multiple lung nodules that do not
fit in a tolerable radiation field; 9).
b Limited disease: Confined to the ipsilateral hemithorax, which can be
safely encompassed within a tolerable radiation field (TNM: T any, N any,
M 0; except T3-T4 due to multiple lung nodules that do not fit in a
tolerable radiation field; 9).
Table 2 - Stage of lung cancer with respect to time (months)
from the date when the patient was diagnosed with cancer (DX)
to the starting date of treatment (TTO), showing the number
of patients at each stage according to the different delays*.
Stage of
lung
cancer
Number of
patients
(%)
Delay between DX
and TTO p1.5
months
Delay between DX
and TTO 41.5
months
Total Total Total
509 (100) 334 (65) 175 (35)
Ia/Ib 37 26 (70) 11 (30)
IIa/IIb 28 14 (50) 14 (50)
IIIa/IIIb 74 46 (62) 28 (38)
IV 274 177 (65) 94 (35)
Extensive 58 40 (69) 18 (31)
Limited 15 08 (53) 07 (47)
Undefined 23 22 (96) 01 (04)
*p value = 0.039 (Fisher’s exact test, p1.5 vs. 41.5 months).
677
CLINICS 2017;72(11):675-680 Impact of delay to start treatment
Abrao FC et al.
Figure 1 - Kaplan Meier curve for mortality due to lung cancer in patients according to time from the patient history (PH) to diagnosis
(DX). The blue line represents the patients diagnosed up to 3 months, and the green line represents patients diagnosed above
3 months.
Figure 2 - Kaplan Meier curve for mortality due to lung cancer in patients according to time from the appointment (first app) to
diagnosis (DX). The blue line represents the patients diagnosed up to 2 months and green line above 2 months.
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than 60 days. On the other hand, in South Korea, Shin et al.
described only the surgical delay for patients with lung
cancer, and the median time from cancer diagnosis to surgery
was 20 days (15). In Finland, for all patients with lung cancer,
the median time from cancer diagnosis to treatment was
15 days (10). Our study did not assess the possible causes
that could explain our results. However, it is noteworthy that
the number of patients who waited more than 30 days to
start treatment is substantial.
Regarding the decrease in survival observed in patients
who started treatment up to 1.5 months after diagnosis,
Myrdal et al. found the same result (11). In both studies, the
number of patients in clinical stages III and IV was higher in
the group treated early (Table 2). Therefore, in agreement
Figure 3 - Kaplan Meier curve for mortality due to lung cancer in patients according to time from diagnosis (DX) to the starting date of
treatment (TTO). The blue line represents the patients that started treatment above 1.5 months and green line up to 1.5 months.
Table 3 - Risk factors (prevalence odds ratio, 95% CI) associated with patient death by univariate and multivariate analyses
(Cox regression).
Risk factors, N (%) Univariate analysis Multivariate analysis Multivariate analysis p value
Age 4 62 years 1.1 (0.9 – 1.3) not included
Gender Male 1.1 (0.9 – 1.4) not included
Histology type of primary tumor
Adenocarcinoma Comparator
Large cell carcinoma 1.3 (0.8 – 2.2)
Squamous cell carcinoma 1.3 (1.0 – 1.6)
Small cell lung cancer 2.3 (1.7 – 3.2)* 2.0 (1.5 – 2.8) o0.001
Stages of cancer
Ia/Ib comparator
IIa/IIb 1.6 (0.8 – 3.2) 2.5 (1.4 – 4.6) 0.002
IIIa/IIIb 2.7 (1.6 – 4.7)* 3.0 (1.7 – 5.4) o0.001
IV 3.7 (2.2 – 6.2)* - ns
Extensive 3.9 (2.2 – 6.9)* - ns
Limited 2.7 (1.3 – 5.6)* - ns
No surgical treatment for lung cancer comparator
Surgical treatment for lung cancer 0.4 (0.3 – 0.6)* 0.6 (0.4 – 0.9) 0.005
Time from PH to DX 4 3 months 1.0 (0.8 – 1.2) not included
Time from first app to DX 4 2 months 1.2 (1.0 – 1.5) not included
Time from DX to TTO o 1.5 months 1.8 (1.4 – 2.2)* 2.1 (1.6 – 2.6) o0.001
*p value o0.05 (univariate analysis by Cox regression).
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with Myrdal et al., we believe that more severe patients,
i.e., those at more advanced stages, end up being prioritized
to start treatment sooner than those at lower stages. The
authors of both studies believe that this phenomenon reflects
the health system’s incapacity to absorb all patients. Perhaps
this deficiency of the public health system could be mini-
mized with the implementation of early detection programs
for lung cancer.
Our study has several limitations. This is a retrospective
study of data from a single reference oncology center. Mortal-
ity data should be interpreted with caution, as the study
included patients who received exclusively palliative treatment
as well as patients with different types of biological tumors
(e.g., small cell carcinoma).
We conclude that there was a reduction in the time to lung
cancer diagnosis over the past two decades. Access to a
specialist plays a crucial role in diagnosis in the public health
system, and in our densely populated area, patients have to
wait a relatively long time to begin treatment. This type of
study is important to alert medical societies and government
health agencies.
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